Clinical Research Directory
Browse clinical research sites, groups, and studies.
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
Sponsor: National Cancer Institute (NCI)
Summary
This phase II MATCH treatment trial identifiesay block the protein tyrosine kinase WEE1 the effects of AZD1775 in patients whose cancer has a genetic change called BRCA mutation. AZD1775 may block a protein called WEE1, which may be needed for growth of cancer cells that express BRCA mutations. Researchers hope to learn if AZD1775 will shrink this type of cancer or stop its growth.
Official title: MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients With Tumors Containing BRCA1 and BRCA2 Mutations
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
35
Start Date
2017-03-13
Completion Date
2026-12-31
Last Updated
2025-10-31
Healthy Volunteers
No
Conditions
Interventions
Adavosertib
Given PO
Locations (1)
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, United States